Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Coripharma and Midas Have Entered into an Exclusive Licensing Partnership
Details : Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.
Brand Name : Raltegravir-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 23, 2020
Lead Product(s) : Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Midas Pharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?